NCT04450550

Brief Summary

Parkinson's disease burdens an increasing number of elderly populations in the country. Parkinson disease is a chronic, progressive neurodegenerative disorder, affects approximately 1% of the population by the age of 65 years and 4% to 5% of the population by the age of 85 years. Mild cognitive impairment in Parkinson's disease leads to Parkinson's disease dementia (PDD) for which currently there is no drug therapy. The existing treatments for PD were associated with side effects and does not offer complete cure. Hence there is a need of alternative therapy which can prevent or delay the onset of PD with less or no side effects. Vestibular stimulation is known to modulate cognitive processing, enhance learning and spatial memory. Vestibular dysfunction is present in PD patients. So long term vestibular stimulation may be effective in enhancing cognition by reducing the cognitive, neurodegenerative, neuroinflammatory changes and behavioral deficits observed as predictors of Mild Cognitive Impairment in Parkinson's disease Dementia. In this project, the plan is to administer electric vestibular nerve stimulation to PD patients which might be effective and ideal treatment with minimum or no side effects in the management of Parkinson's disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for not_applicable parkinson-disease

Timeline
Completed

Started Jul 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 11, 2020

Completed
18 days until next milestone

First Posted

Study publicly available on registry

June 29, 2020

Completed
1.1 years until next milestone

Study Start

First participant enrolled

July 26, 2021

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2022

Completed
Last Updated

April 27, 2023

Status Verified

April 1, 2023

Enrollment Period

1.3 years

First QC Date

June 11, 2020

Last Update Submit

April 26, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Unified Parkinson's disease Rating Scale (UPDRS)

    The UPDRS has been the most used Parkinsons disease scale. It is a 42 item questionnaire grouped into four subscales. A score of 199 on the UPDRS scale represents the worst (total disability) with a score of zero representing (no disability).

    12 weeks

Secondary Outcomes (13)

  • Berg Balance Scale (BBS)

    12 weeks

  • Range of motion (ROM)

    12 weeks

  • Muscle Strength

    12 weeks

  • Assessment of hand-eye coordination

    12 weeks

  • Assessment of spatial memory

    12 weeks

  • +8 more secondary outcomes

Study Arms (2)

Active

ACTIVE COMPARATOR
Device: VeNS device

Sham

SHAM COMPARATOR
Device: Sham VeNS device

Interventions

VeNS treatment

Active

Sham treatment of VeNS

Sham

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Fulfilled the Hoehn \& Yahr Classification of Disability 79,80 stage 1-2
  • Ambulate with or without an assistive device for at least 50 feet
  • Were able to get up and down from the floor with minimal assistance or less and
  • Score of 24 or above on the Folstein Mini-Mental State Exam

You may not qualify if:

  • Decline in immune function such as pneumonia or systemic infection
  • Progressive degenerative disease besides PD
  • Spinal fusion or other orthopedic surgery in the past six months
  • Mental disease/psychosis such as dementia
  • Greater than minimal assistance required for gait and transfers
  • Inability to make regular time commitments to the scheduled intervention sessions
  • Experience with regular practice of any form of vestibular stimulation within the past year

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

RD Gardi Medical College

Ujjain, Madhya Pradesh, 456001, India

Location

Related Publications (2)

  • Kumar Goothy SS, Gawarikar S, Choudhary A, Govind PG, Purohit M, Pathak A, Chouhan RS, Ali Z, Tiwari M, Khanderao MV. Effectiveness of electrical vestibular nerve stimulation on the range of motion in patients with Parkinson's disease. J Basic Clin Physiol Pharmacol. 2022 Oct 10;34(6):791-795. doi: 10.1515/jbcpp-2022-0138. eCollection 2023 Nov 1.

  • Kumar Goothy SS, Gawarikar S, Choudhary A, Gajanan Govind P, Purohit M, Pathak A, Chouhan RS, Vijay Khanderao M. Effectiveness of electrical vestibular nerve stimulation as adjunctive therapy to improve the cognitive functions in patients with Parkinson's disease. J Basic Clin Physiol Pharmacol. 2022 Sep 16;34(1):77-82. doi: 10.1515/jbcpp-2022-0066. eCollection 2023 Jan 1.

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • Sai Sailesh Kumar Goothy

    RD Gardi Medical College, Ujjain

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 11, 2020

First Posted

June 29, 2020

Study Start

July 26, 2021

Primary Completion

November 1, 2022

Study Completion

November 1, 2022

Last Updated

April 27, 2023

Record last verified: 2023-04

Locations